Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: A meta-analysis

BMJ

Volumn 309, Issue 6950, 1994, Pages 299-

  Leizorovicz, A ^a   Simonneau, G ^a   Decousus, H ^a   Boissel, J P ^a  

^a Service de Pharmacologie Clinique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG COMPARISON; DRUG EFFICACY; DRUG SAFETY; FRANCE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

DOSE-RESPONSE RELATIONSHIP, DRUG; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INCIDENCE; ODDS RATIO; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; THROMBOPHLEBITIS;

EID: 0027932867     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.309.6950.299     Document Type: Article

References (49)

1. Barritt DW Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960; i: 1309-12.
2. Brandjes DPM Heijboer H Buller HR Rijk M Jagt H ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 327: 1485–9.
3. Gallus A Jackaman J Tillett J Mills W Wycherley A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986; ii: 1293-6.
4. Hull RD Raskob GE Rosenbloom D Panju AA Brill-Edwards P Ginsberg JS, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322: 1260–4.
5. Carter CJ Kelton JG Hirsh J Cerskus A Santos AV Gent M. The relationship between the haemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239–45.
6. Frydman AM Bara L Le Roux Y Wolern M Chauliac F Samama M. The antithrombotic activity and pharmacokinetics of Enoxaparin, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 1988; 8: 609–18.
7. Leizorovicz A Haugh MC Chapuis FR Samama MM Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992; 305: 913–20.
8. Nurmohamed MT Rosendaal FR Buller HR Dekker E Hommes DW Vandenbroucke JP, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340: 152–6.
9. Boissel JP Bossard N. Registry of multicenter clinical trials: twelfth and thirteenth report, 1990-1991. Thromb Haemost 1992; 68: 752–8.
10. Arnesen H Heilo A Jakobsen E Ly B Skaga E. A prospective study of streptokinase and heparin in the treatment of deep vein thrombosis. Acta Medica Scandinavica 1978; 203: 457-63.
11. Marder VJ Soulen RL Atichartakarn V Budzynski AZ Parulekav S Kim J, et al. Quantitative venographic assessment of deep venous thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977; 89: 1018–29.
12. Berlin JA Laird NM Sacks HS Chalmers TC. A comparison of statistical methods for combining event rates from clinical trials. Stat Med 1989; 8: 141–51.
13. Boissel JP Blanchard J Panak E Peyrieux JC Sacks H. Considerations for the meta-analysis of randomized clinical trials. Summary of a panel discussion. Controlled Clin Trials 1989; 10: 254–81.
14. Breslow NE Day NE. Statistical methods in cancer research. Lyons: IARC Press, 1980.
15. Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 10: 101–29.
16. DerSimonian R Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–88.
17. Mantel N Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719–48.
18. Yusuf S Peto R Lewis J Collins R Sleigh P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335–71.
19. Hauck WW Anderson S Leahy FJI. Finite sample properties of some old and some new estimators of a common odds ratio from multiple 2x2 tables. Journal of the American Statistical Association 1982; 77: 145–52.
20. Thompson SG Pocock SJ. Can meta-analyses be trusted? Lancet 1991; 338: 1127–30.
21. Lau JL Antman EM Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327: 248–54.
22. Collaborative European Multicentre Study. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1991; 65: 251–6.
23. Albada J Nieuwenhuis HK Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study. Circulation 1989; 80: 935–40.
24. Bratt G Aberg W Johansson M Tornebohm E Granqvist S Lockner D. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (D.V.T.). Thromb Haemost 1990; 64: 506–10.
25. Bratt G Tornebohm E Granqvist S Aberg W Lockner D. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost 1985; 54: 813–7.
26. Etude Multicentrique Francaise. Traitement des thromboses veineuses profondes constituees. Etude comparative d'un fragment d'heparine de bas poids moleculaire (Fragmine(???)) administree par voie sous-cutanee et de l'heparine standard administree par voie intraveineuse continue. Rev Med Interne 1989; 10: 375–81.
27. Faivre R Neuhart Y Kieffer Y Aplet F Magnino D Didier D, et al. Un nouveau traitment des thromboses veineuses profondes: les fractions d'heparine de bas poids moleculaire. Etude randomisee. Presse Med 1988; 17: 197–200.
28. Harenberg J Huck K Bratsch H Stehle G Dempple Ce Mall K, et al. Therapeutic application of subcutaneous low molecular-weight heparin in acute venous thrombosis. Haemostasis 1990; 20 (suppl 1): 205-19.
29. Holm HA Ly B Handeland GF Abildgaard U Arnesen KE Gottschalk P, et al. Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis 1986; 16 (suppl 2): 30-7.
30. Hull RD Raskob GE Pineo GF Green D Trowbridge AA Elliott G, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992; 326: 975–82.
31. Kakkar VV Murray WJG Walters BL Gelister J Malone P Jones D. Treatment of deep vein thrombosis using a low molecular weight heparin (LMWH) (CY216). Thromb Haemost 1985; 54: 35(abstract).
32. Lopaciuk S Meissner AJ Filipecki S Zawilska K Sowier J Ceisielski L, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemost 1992; 68: 14–8.
33. Notarbartolo A Salanitri G Davi G Averna M Barbagallo C Catalano I. Low molecular weight heparin in the short and long-term treatment of deep vein thrombosis in diabetic subjects. Med Praxis 1988; 9: 1–13.
34. Prandoni P Lensing AWA Buller HR Carter M Cogo A Vigo M, et al. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal deep vein thrombosis. Lancet 1992; 339: 441–5.
35. Simonneau G Charbonnier B Decousus H Planchon B Franco A Ninet J, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment of proximal vein thrombosis. A multicenter randomized trial: DVTENOX study. Arch Intern Med 1993; 153: 1541–6.
36. Tedoldi A Botticella F Maloberti MR. Antithrombophilic effect of low molecular weight heparins in patients with deep vein thrombosis. Clinical Trials Meta-Analyses 1993; 28: 215–25.
37. Zanghi' M Morici V Costanzo M Astuto L Salanitri G. Deep vein thrombosis of the legs: new therapy by means of low molecular weight heparins. Journal of International Medical Research 1988; 16: 474–84.
38. Lindmarker P Holmstrom M Granqvist S Johnsson H Lockner D. Fragmin once daily subcutaneously in a fixed-dose compared with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis [abstract]. Thromb Haemost 1993; 69: 648.
39. Leizorovicz A Haugh MC Boissel JP. Meta-analysis and multiple publication of clinical trial reports. Lancet 1992; 340: 1102–3.
40. Prandoni P Vigo M Cattelan AM Ruol A. Treatment of deep venous thrombosis by fixed doses of a low molecular weight heparin (CY216). Haemostasis 1990; 20 (supl 1): 220-3.
41. Boissel JP Collet JP Moleur P Haugh M. Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharmacol 1992; 43: 235–44.
42. Goldberg RJ Seneff M Gore JM Anderson F Greene H Wheeler B, et al. Occult malignant neoplasm in patients with deep venous thrombosis. Arch Intern Med 1987; 147: 251–3.
43. Griffin MR Stanson AW Brown ML Hauser MF O'Fallon WM Anderson FA, et al. Deep venous thrombosis and pulmonary embolism. Risk of subsequent malignant neoplasms. Arch Intern Med 1987; 147: 1907–11.
44. Prandoni P Lensing AWA Buller HR Cogo A Prins MH Cattelan AM, et al. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128–33.
45. Linblad B Sternby NH Bergqvist D. Incidence of venous thrombosis verified by necropsy over 30 years. BMJ 1991; 302: 709–11.
46. Bara L Samama MM. The need for standardization of low molecular weight heparin (LMWH) [abstract]. Thromb Haemost 1986; 56: 418.
47. Keber I Potisk K Keber M Stegnar M Vene N. Physical activity releases tissue plasminogen activator from exercising parts of body. Thromb Haemost 1987; 58 (suppl II): 91 (abstract).
48. Hommes DW Bura A Mazzolai L Buller HR ten Cate JW. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep venous thrombosis. A meta- analysis. Ann Intern Med 1992; 116: 279–84.
49. Baker SR Stacey MC Jopp-McKay AG Hoskin SE Thompson PJ. Epidemiology of chronic venous ulcers. Br J Surg 1991; 78: 864–7.